Abstract

BACKGROUND: Diabetes mellitus (DM) continues to increase with currently more than 463 million people in the world live with DM. One of the causes of Type 2 DM (T2DM) is insulin resistance. Determining laboratory-based tests for early identification of T2DM is important. One of the tests developed was the detection of homeostatic model assessment – insulin resistance (HOMA-IR) levels. AIM: Using chlorogenic acid found in coffee leaves as antidiabetic agent for alternative treatments in DM, this research is conducted to understand the effect of Coffee Arabica Gayo Leaf Extract (Coffea arabica L.) in decreasing HOMA-IR levels in T2DM rats. MATERIALS AND METHODS: Thirty-five male Wistar rats (Rattus norvegicus) had T2DM induced using a combination of feeding a high-fat diet for 5 weeks followed by multiple intraperitoneal injections of low-dose streptozotocin (30 mg/kgBW), divided into 7 groups (2 groups that did not receive treatment [K1 and K3] and 5 groups that received treatment [K2, K4, K5, K6, K7]). The extract was administered with dosage 150, 200, and 250 mg/kgBW/day through a nasogastric tube for 30 days. Then, the HOMA-IR value will be obtained by multiplying fasting plasma insulin by fasting plasma glucose, then divide by a constant of 22.5. RESULTS: The study showed a significant difference before and after treatment, p value was < 0.05, which a decrease HOMA-IR levels (p = 0.002) after given Coffee Arabica Gayo Leaf Extract at 200 and 250 mg/kgBW/day to Wistar rats for 30 days. The decrease HOMA-IR levels are greater than The T2DM group that received metformin and group without treatment. CONCLUSION: Coffee Arabica Gayo Leaf Extract can significantly decrease HOMA-IR levels at a dose of 200 and 250 mg/kgBW. The decrease of HOMA-IR levels is greater than The T2DM group that received metformin and group without treatment.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.